巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Protara Therapeutics

TARA
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Protara Therapeutics - 延遲價格・最後更新於 14/01 12:15
最高位
6.380
最低位
6.100
開市價
--
前收市價
6.320
成交量(千)
1.42
成交額(百萬)
0.08
買入
--
賣出
--
每手股數
--
市值(百萬)
71.68
市盈率
--
息率
--
差價
--
52週高低
25.200 - 5.940
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Protara Therapeutics
證券代碼
TARA.US
所屬板塊
Biotechnology
公司業務
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
發行量
11235731
公司總部
345 Park Avenue South, 3rd Floor
公司網址
http://www.protaratx.com
公司電郵
inquiries@artaratx.com
公司電話
+1 646 844-0337
暫無內容

關於

Protara Therapeutics(TARA.US)所屬的行業板塊為Biotechnology。
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
詳細公司背景可參考: http://www.protaratx.com